Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Targeted Genomic Analysis of Human Cancers
Rutgers, The State University of New Jersey
1,100 participants
Feb 1, 2013
OBSERVATIONAL
Conditions
Summary
This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.
Eligibility
Inclusion Criteria4
- Karnofsky/Lansky performance score >= 30
- A signed written informed consent
- Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
- Paraffin blocks of the patient's tumor tissue are available and accessible for analysis
Exclusion Criteria2
- Karnofsky/Lansky performance score < 30
- Life expectancy < 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo collection of blood samples
Correlative studies
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02688517